Open AccessTargeting Prolactin Receptor (PRLR) Signaling in PRLR‐Positive Breast and Prostate Cancer
Author(s) -
O'Sullivan Ciara C.,
Bates Susan E.
Publication year - 2016
Publication title -
the oncologist
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.176
H-Index - 164
eISSN - 1549-490X
pISSN - 1083-7159
DOI - 10.1634/theoncologist.2016-0108
Subject(s) - medicine , prolactin receptor , prostate cancer , breast cancer , prolactin , oncology , prostate , cancer , pharmacodynamics , pharmacokinetics , hormone
In this issue of The Oncologist , Agarwal et al. report negative results from a phase I trial of LFA102. Although “negative” in terms of antitumor activity, the study provides useful pharmacokinetic and pharmacodynamic information. Future trials evaluating PRLR blockers alone and in combination with other agents may still be warranted in patients with breast and prostate cancer.